ABE1943

Anti-HOXB13 Antibody

from rabbit, purified by affinity chromatography

• Synonym(s): Homeobox protein Hox-B13, HOXB13
• UNSPSC Code: 12352203
• NACRES: NA.41
• eCl@ss: 32160702
• Conjugate: unconjugated
• Clone: polyclonal
• Application: ICC, IHC, WB
• Citations: -

Properties

• biological source: rabbit
• Quality Segment: 100
• conjugate: unconjugated
• antibody form: affinity isolated antibody
• antibody product type: primary antibodies
• clone: polyclonal
• purified by: affinity chromatography
• species reactivity: human
• technique(s): immunocytochemistry: suitable, immunohistochemistry: suitable, western blot: suitable
• NCBI accession no.: NP_006352
• UniProt accession no.: Q92826
• shipped in: wet ice
• target post-translational modification: unmodified
• Gene Information: human ... HOXB13(10481)

Description

General description

Homeobox protein Hox-B13 (UniProt Q92826) is encoded by the HOXB13 (also known as PSGD) gene (Gene ID 10481) in human. HOXB13 is a homeobox gene family member whose expression is restricted to prostate tissues and is highly correlated with that of androgen receptor (AR). Hox-B13 suppresses androgen-stimulated AR activity via direct AR interaction and thereby inhibits androgen-dependent (AD) prostate cancer (PCa) growth under androgen-rich conditions. On the other hand, HOXB13 is also known to be over-expressed in castration-resistant PCa (CRPC), where it plays a dichotomic role in promoting androgen-independent (AI) PCa growth. The zinc level in human prostate is markedly diminished in prostatic epithelial tumors and continues to decline during progression towards AI growth. HOXB13 over-expression upregulates transcription of its target genes SLC30A10 (ZnT10) and SLC30A4 (ZnT4) for zinc output transporters, which are responsible for the reduction in zinc level in CRPC. The diminished intracellular zinc level in turn stimulates NF-κB signaling and promotes invasion and metastasis of CRPC cells.

~35 kDa observed

Immunogen

KLH-conjugated linear peptide corresponding to the C-terminus of human HOXB13.

Application

This Anti-HOXB13 Antibody is validated for use in Western Blotting, Immunocytochemistry and Immunohistochemistry for the detection of HOXB13.

Western Blotting Analysis: A representative lot detected HOXB13 expression in human prostate cancer cell lines MDA PCa 2b, LNCaP, and C4-2, but not in prostate cancer DU145, PC3, CWR22Rv-1, or the non-tumorigenic prostate epithelial line P69 (Kim, Y.R., et. al. (2010). Mol Cancer. 9:124).
Immunocytochemistry Analysis: A representative lot detected HOXB13 nuclear expression in MDA PCa 2b and LNCaP, but not PC3 or DU145, human prostate cancer cell lines (Kim, Y.R., et. al. (2010). Mol Cancer. 9:124).
Immunohistochemistry Analysis: A representative lot detected differential HOXB13 expressions among various androgen-dependent (AD) and androgen-independent (AI) human prostate cancer tissues (Kim, Y.R., et. al. (2010). Mol Cancer. 9:124; Kim, Y.R., et. al. (2014). Oncogene. 33(37):4558-4567).

Biochem/physiol Actions

This polyclonal antibody selectively reacts with human HOXB13, but not the homologous HOXA13 or HOXD13.

Physical form

Purified rabbit polyclonal antibody in buffer containing 0.1M Tris-HCI, pH 8.0, and 0.1% soidum azide.

Analysis Note

Evaluated by Western Blotting in LNCaP cell lysate.

Western Blotting Analysis: 0.2 µg/mL of this antibody detected HOXB13 in 10 µg of LNCaP cell lysate.

Other Notes

Concentration: Please refer to lot specific datasheet.

Safety Information

• Storage Class: 12 - Non Combustible Liquids
• wgk: nwg
• flash_point_f: Not applicable
• flash_point_c: Not applicable